University of Toronto,Canada and Chinese Academy of Medical Sciences/Peking Union Medical College, China
Dr. Limin Chen, affiliate scientist with the University of Torontoa and also a professor with the Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), now is the director and chief scientific officer of the center for transfusion transmitted diseases, Institute of Blood Transfusion (IBT), CAMS/PUMC, Member of the American Association for Studies of Liver Diseases (AASLD) and Canadian Association for Studies of Liver (CASL). He obtained his MD, MSc in biochemistry and molecular biology in China, PhD in molecular genetics at the University of Toronto. Dr. Chen obtained his postdoctoral training both at the Merck Research Laboratories and at the Harvard Medical School . Currently Dr. Chen’s research focuses on the virus-host interaction of the hepatitis viruses, especially HCV and HBV. He pioneered the work on identification of the response signature of HCV non-response to interferon treatment and proposed a novel mechanism on how HCV exploits host innate immune response to benefit its persistent infection and resistance to interferon-based therapy.
Abstract : Activation of the ubiquitin-like ISG15/USP18 signaling pathway contributes to interferon resistance of HCV and HBV